Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Invesco Ltd. (IVZ) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Invesco Ltd. — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: Invesco Ltd. is far larger — about 17.8× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Invesco Ltd. pays a 2.86% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Invesco Ltd. for 77 Days on average.

FEPIIVZ
Market Cap
$746.48M$13.28B
Volume
334,3373,698,033
Sector
Income / Options OverlayFinancials
52-Week High
$49.54$33.31
52-Week Low
$37.98$22.44
Typical Hold Time
56 Days77 Days
Enterprise Value
—$23.45B
Dividend Yield
—2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $43.51, down 0.18% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF employs a covered call strategy on AI and tech stocks, generating high weekly dividends but facing capped upside. Recent news highlights its 25% yield but notes underperformance versus peers in total return.

The outlook is mixed: high income appeals, but concentration in volatile tech and covered call limitations pose risks. Investors seeking yield may find value, yet must weigh potential underperformance if tech momentum slows. Risks include sector volatility and strategy constraints in rising markets.

Invesco Ltd.

Invesco (IVZ) trades at $29.51, down 3.25% today, with bearish technical signals dominating. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Despite negative net income margins in 2025, operating cash flow remains strong at $1.53 billion, and analyst consensus leans toward Hold with a $33.71 price target. Recent news highlights ETF expansions and AUM growth to $2.56 trillion in August 2026.

The outlook is cautious; IVZ faces profitability challenges with negative ROE and net margins, but solid cash flow and analyst buy ratings (42.86%) suggest recovery potential. Risks include earnings volatility and competitive ETF pressures, while institutional sentiment is neutral. The stock's current price near the low end of analyst targets ($28-$41) may appeal to value investors betting on operational improvements.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FEPI
25% Buy75% Sell
Avg holding period · 56 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →